SEC Form 4 · accession 0001209191-15-041969
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James F Oliviero III
Officer — Chief Financial Officer
Period of report
May 12, 2015
Accepted (ET)
May 12, 2015 · 7:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 12, 2015 | M | 18,333 | $2.53 | A | 188,071 | D | |
| Common StockF1 | May 12, 2015 | M | 23,278 | $2.78 | A | 211,349 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F2 | $2.53 | May 12, 2015 | M | 18,333 | D | Jan 2, 2015 | Jan 2, 2022 | Common Stock | 18,333 | 0 | D |
| Stock Options (right to buy)F3 | $2.78 | May 12, 2015 | M | 23,278 | D | Apr 2, 2015 | Jan 2, 2023 | Common Stock | 23,278 | 13,966 | D |
Explanation of responses
- F1Includes 45,516 shares of restricted stock.
- F2The options were granted on January 2, 2012 and were vested in full on January 2, 2015.
- F3The options were granted on January 2, 2013. The options exercised were fully vested on April 2, 2015. The remaining 13,966 options vest in equal installments on July 2, 2015, October 2, 2015 and January 2, 2016.